PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 236-246

  Peyrou, Marion ^a   Bourgoin, Lucie ^a   Foti, Michelangelo ^a,b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b University Medical Centre   (Switzerland)

Author keywords

Fibrosis; Hepatocellular carcinoma; Insulin resistance; Liver; Obesity; PTEN; Steatosis

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; EARLY GROWTH RESPONSE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MYC PROTEIN; NOTCH1 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C JUN; PROTEIN CBF 1; PROTEIN P300; PROTEIN P53; PROTEIN SPRY2; SOMATOMEDIN B; SPROUTY PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

ENZYME ACTIVITY; EPIGENETICS; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; EPIGENESIS, GENETIC; FATTY LIVER; HUMANS; LIVER; LIVER NEOPLASMS; MICE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PTEN PHOSPHOHYDROLASE; RNA PROCESSING, POST-TRANSCRIPTIONAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77952575909     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282095     Document Type: Review

References (93)

1. Adams LA, Angulo P: Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-1133. (Pubitemid 41224168)
2. Contos MJ, Choudhury J, Mills AS, Sanyal AJ: The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:481-500, vii.
3. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687.
4. Choudhury J, Sanyal AJ: Insulin resistance in NASH. Front Biosci 2005;10:1520-1533.
5. Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest 2000;106:473-481.
6. Boden G: Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006;6:177-181.
7. Morino K, Petersen KF, Shulman GI: Molecular mechanisms of insu lin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006;55 (suppl 2):S9-S15.
8. Gressner AM, Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99.
9. Avila MA, Berasain C, Sangro B, Prieto J: New therapies for hepatocellular carcinoma. Oncogene 2006;25:3866-3884.
10. Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
11. Vinciguerra M, Foti M: PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling. Arch Physiol Biochem 2006;112:89-104.
12. Vinciguerra M, Foti M: PTEN at the crossroad of metabolic diseases and cancer in the liver. A nn Hepatol 2008;7:192-199.
13. Chu EC, Tarnawski AS: PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 2004;10:RA235-RA241.
14. Tamguney T, Stokoe D: New insights into PTEN. J Cell Sci 2007;120:4071-4079.
15. Planchon SM, Waite KA, Eng C: The nuclear affairs of PTEN. J Cell Sci 2008;121:249-253.
16. Chow LM, Baker SJ: PTEN function in normal and neoplastic growth. Cancer Lett 2006;241:184-196.
17. Downes C P, Perera N, Ross S, Leslie NR: Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN. Biochem Soc Symp 2007: 69-80.
18. Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-5510.
19. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007;128:157-170.
20. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280:1614-1617.
21. Kotelevets L, van Hengel J, Bruyneel E, Mareel M, van Roy F, Chastre E: The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J Cell Biol 2001;155:1129-1135.
22. Kotelevets L, van Hengel J, Bruyneel E, Mareel M, van Roy F, Chastre E: Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J 2005;19:115-117.
23. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL: Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007;37:389-396. (Pubitemid 46605424)
24. Zysman MA, Chapman WB, Bapat B: Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 2002;16 0: 795-800.
25. Pan L, Lu J, Wang X, Han L, Zhang Y, Han S, Huang B: Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 2007;109:1676-1688.
26. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I: The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001;3:1124-1128.
27. Moorehead RA, Hojilla CV, De Belle I, Wood GA, Fata JE, Adamson ED, Watson KL, Edwards DR, Khokha R: Insulin-like growth factor-II regulates PTEN expression in the mammar y gland. J Biol Chem 2003;278:50422-50427.
28. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW: Regulation of PTEN transcription by p53. Mol Cell 2001;8:317-325.
29. Zhang W, Wu N, Li Z, Wang L, Jin J, Zha XL: PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther 2006;5:1008-1014.
30. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB: The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 2006;281:4816-4822.
31. Shen YH, Zhang L, Gan Y, Wang X, Wang J, LeMaire SA, Coselli JS, Wang XL: Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. J Biol Chem 2006;281:7727-7736.
32. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, Parsons R, Zuniga-Pflucker JC, Dominguez M, Ferrando AA: Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007;13:1203-1210.
33. Vasudevan KM, Gurumurthy S, Rangnekar VM: Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 2004;24:1007-1021.
34. Vinciguerra M, Veyrat-Durebex C, Moukil MA, Rubbia-Brandt L, Rohner-Jeanrenaud F, Foti M: PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 20 08;134: 268-280.
35. Chappell WH, Green TD, Spengeman JD, McCubrey JA, Akula SM, Bertrand FE: Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. Cell Cycle 2005;4:1389-1395.
36. Whelan JT, Forbes SL, Bertrand FE: CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle 2007;6:80-84.
37. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT, Reddy SA, Sabapathy K: c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 2007;14:218-229.
38. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-658.
39. Pezzolesi MG, Platzer P, Waite KA, Eng C: Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet 2008;82:1141-1149.
40. Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M: Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009;49:1176-1184.
41. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008;9:405-414.
42. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-433.
43. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, Gunn A, Nakagawa Y, Shimano H, Todorov I, Rossi JJ, Natarajan R: TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009;11:881-889.
44. Vinciguerra M, Carrozzino F, Peyrou M, Carlone S, Montesano R, Benelli R, Foti M: Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. J Hepatol 2009;50:1132-1141.
45. Wang X, Jiang X: Post-translational regulation of PTEN. Oncogene 2008;27:5454-5463.
46. Salmena L, Carracedo A, Pandolfi PP: Tenets of PTEN tumor suppression. Cell 2008;133:403-414.
47. Torres J, Rodriguez J, Myers MP, Valiente M, Graves JD, Tonks NK, Pulido R: Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem 2003;278:30652-30660.
48. Arevalo MA, Rodriguez-Tebar A: Activation of casein kinase II and inhibition of phosphatase and tensin homologue deleted on chromosome 10 phosphatase by nerve growth factor/p75NTR inhibit glycogen synthase kinase-3beta and stimulate axonal growth. Mol Biol Cell 2006;17:3369-3377.
49. Maccario H, Perera NM, Davidson L, Downes CP, Leslie NR: PTEN is destabilized by phosphorylation on Thr366. Biochem J 2007;405:439-444.
50. Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, Tang L, Hla T, Zeng R, Li L, Wu D: Regulation of PTEN by Rho small GTPases. Nat Cell Biol 2005;7:399-404.
51. Okumura K, Mendoza M, Bachoo RM, De-Pinho RA, Cavenee WK, Furnari FB: PCAF modulates PTEN activity. J Biol Chem 2006;281:26562-26568.
52. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP: Redox regulation of PI 3-kinase signalling via inactivation of PTEN. Embo J 2003;22:5501-5510.
53. Seo JH, Ahn Y, Lee SR, Yeol Yeo C, Chung Hur K: The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol Biol Cell 2005;16:348-357.
54. Wang X, Trotman L C, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007;128:129-139.
55. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X, Pandolfi PP: Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007;128:141-156.
56. Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, Whang YE: Evidence for regulation of the PTEN tumor suppressor by a membranelocalized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci USA 2000;97:4233-4238.
57. Valiente M, Andres-Pons A, Gomar B, Torres J, Gil A, Tapparel C, Antonarakis SE, Pulido R: Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J Biol Chem 2005;280:28936-28943.
58. Tang Y, Eng C: p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction. Cancer Res 2006;66:6139-6148.
59. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM: PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 2006;25:910-920.
60. Okahara F, Ikawa H, Kanaho Y, Maehama T: Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem 2004;279:45300-45303. (Pubitemid 39491510)
61. Hao LS, Zhang XL, An JY, Karlin J, Tian XP, Dun ZN, Xie SR, Chen S: PTEN expression is down-regulated in liver tissues of rats with hepatic fibrosis induced by biliary stenosis. APMIS 2009;117:681-691.
62. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, Schmittgen TD, Croce C, Ghoshal K, Jacob ST: Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009;50:1152-1161.
63. Tilg H, Moschen AR: Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008;19:371-379.
64. Zhang L, Yu Q, He J, Zha X: Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines. Mol Cell Biochem 2004;262:25-33.
65. Mahimainathan L, Das F, Venkatesan B, Choudhury GG: Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 2006;55:2115-2125.
66. Yang Y, Zhou F, Fang Z, Wang L, Li Z, Sun L, Wang C, Yao W, Cai X, Jin J, Zha X: Post-transcriptional and post-translational regulation of PTEN by transforming growth factor-beta1. J Cell Biochem 2009;106:1102-1112.
67. Kim S, Domon-Dell C, Kang J, Chung DH, Freund JN, Evers BM: Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop. J Biol Chem 2004;279:4285-4291.
68. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, Burger R, Gramatzki M, Blumert C, Bauer K, Cvijic H, Ullmann AK, Stadler PF, Horn F: Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330-1333.
69. Barbieri SS, Ruggiero L, Tremoli E, Weksler BB: Suppressing PTEN activity by tobacco smoke plus interleukin-1beta modulates dissociation of VE-cadherin/beta-catenin complexes in endothelium. Arterioscler Thromb Vasc Biol 2008;28:732-738.
70. Ning K, Miller LC, Laidlaw HA, Burgess LA, Perera NM, Downes CP, Leslie NR, Ashford ML: A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells. EMBO J 2006;25:2377-2387.
71. Lam JB, Chow KH, Xu A, Lam KS, Liu J, Wong NS, Moon RT, Shepherd PR, Cooper GJ, Wang Y: Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLoS One 2009;4:e4968.
72. Lee KS, Park SJ, Hwang PH, Yi HK, Song CH, Chai OH, Kim JS, Lee MK, Lee YC: PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J 2005;19:1033-1035.
73. Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C: Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer 2006;118:2390-2398.
74. Budhu A, Wang XW: The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006;80:1197-1213.
75. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M, Mak TW: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-1178.
76. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasa ki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T: Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113:1774-1783.
77. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu H: Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity (corrected). Proc Natl Acad Sci USA 2004;101:2082-2087.
78. Lackey J, Barnett J, Davidson L, Batty IH, Leslie NR, Downes CP: Loss of PTEN selectively desensitizes upstream IGF1 and insulin signa ling. Oncogene 2007;26:7132-7142.
79. White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW, Hogaboam CM, Flaherty KR, Martinez FJ, Kontos CD, Toews GB: Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10). Am J Respir Crit Care Med 2006;173:112-121.
80. White ES, Thannickal VJ, Carskadon SL, Dickie EG, Livant DL, Markwart S, Toews GB, Arenberg DA: Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: a role for phosphatase and tensin homologue deleted on chromosome 10. Am J Respir Crit Care Med 2003;168:436-442.
81. Kuwano K: PTEN as a new agent in the fight against fibrogenesis. Am J Respir Crit Care Med 2006;173:5-6.
82. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HY, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM: Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002;110:737-749.
83. Leslie NR, Yang X, Downes CP, Weijer CJ: PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol 2007;17:115-125.
84. Dong-Dong L, Xi-Ran Z, Xiang-Rong C: Expression and significance of new tumor suppressor gene PTEN in primary liver cancer. J Cell Mol Med 2003;7:67-71.
85. Yao YJ, Ping XL, Zhang H, Chen FF, Lee PK, Ahsan H, Chen CJ, Lee PH, Peacocke M, Santella RM, Tsou HC: PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999;18:3181-3185.
86. Zhang D, Brodt P: Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003;22:974-982.
87. Leslie NR, Yang X, Downes CP, Weijer CJ: The regulation of cell migration by PTEN. Biochem Soc Trans 2005;33:1507-1508.
88. Furukawa K, Kumon Y, Harada H, Kohno S, Nagato S, Teraoka M, Fujiwara S, Nakagawa K, Hamada K, Ohnishi T: PTEN gene transfer suppresses the invasive potential of human malignant gliomas by regulating cell invasion-related molecules. Int J Oncol 2006;29:73-81.
89. Laurent-Puig P, Zucman-Rossi J: Genetics of hepatocellular tumors. Oncogene 2006;25:3778-3786.
90. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, Fan ST: Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006;12:5369-5376.
91. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM: Obesity and hepatocellular carcinoma. Gastroenterology 2004;127:S97- S103.
92. El-Serag HB, Hampel H, Javadi F: The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-380.
93. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.